2023-10-04 10:59:36
ELI LILLY (I1F-MC-RHBY) – Latin Clinical Trial Center

ELI LILLY (I1F-MC-RHBY)

A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial Spondyloarthritis

Join the discussion 28 Comments

Leave a Reply